Genomics
A genuinely profitable, self-funded in-vivo gene-therapy platform whose entire growth narrative now rests on ex-US VYJUVEK launches (US is flat) plus an unhedged binary KB707/NSCLC option — priced at ~23x sales as if both already work.
Research
The verdict
A genuinely profitable, self-funded in-vivo gene-therapy platform whose entire growth narrative now rests on ex-US VYJUVEK launches (US is flat) plus an unhedged binary KB707/NSCLC option — priced at ~23x sales as if both already work.
Krystal is a fully integrated, commercial-stage in-vivo gene-therapy company built on a proprietary, engineered herpes-simplex-virus-1 (HSV-1) vector platform. The platform's defining trait: the vectors are re-dosable (HSV-1 does not integrate into the host genome and carries a large payload), so therapies can be applied topically/locally and re-administered — unlike AAV or autologous cell therapies, which are typically one-shot and immunogenic on re-dose.
The business has exactly one commercial product: VYJUVEK (beremagene geperpavec-svdt; "B-VEC"), a re-dosable, off-the-shelf topical gene therapy that delivers two copies of the COL7A1 gene directly onto open wounds to treat dystrophic epidermolysis bullosa (DEB) — a rare monogenic skin disease ("butterfly children") with ~3,000 patients in the US and ~9,000 worldwide. VYJUVEK is the first-ever re-dosable gene therapy and the first corrective (vs palliative) DEB treatment.
VYJUVEK has generated $730.3M cumulative net product revenue since the Aug-2023 US launch. No commercial-layer files exist for the genomics beat (all wiki pointers missing), so Lenses 1–4 are filing- and web-grounded rather than KB-grounded.
The defining structural fact: Krystal owns its manufacturing end-to-end. Two in-house commercial-scale CGMP facilities in Pittsburgh:
Chain map: raw materials / excipients (limited number of third-party suppliers — a named single-source risk in the 10-K) → Krystal ANCORIS/ASTRA (manufacture, fill, test, package) → specialty-pharmacy/distributor channel → administering HCP / patient-at-home. For clinical inhaled assets (KB407, KB408, inhaled KB707) the Aerogen Solo / Aerogen Ultra nebulizer is a named device dependency.
Chokepoints: (1) a "limited number of third-party suppliers for some components and materials" — the 10-K flags supplier non-performance / raw-material shortage / contamination as a production risk; (2) single-facility concentration risk historically (now mitigated by ANCORIS + ASTRA dual-site); (3) the specialty-distributor channel itself (Lens 4 concentration). Vertical integration is the moat (control of quality, lead time, cost, and IP) and the concentration risk — a contamination/regulatory event at one Pittsburgh campus hits all global supply.
Moat verdict: real and platform-deep on the science/manufacturing axis; thin on the commercial axis (one drug, one disease, concentrated channel). The durable question is whether the platform produces a second approved product before DEB saturates.
One product, so the meaningful cut is geography — and it is the single most important slide in the dossier. Q1-2026 net product revenue by region:
| Region | Q1-2026 | Q1-2025 | YoY |
|---|---|---|---|
| United States | $87.5M | $88.2M | −0.8% (flat/declining) |
| Europe | $20.7M | $0 | new (Germany) |
| Japan | $8.2M | $0 | new |
| Total | $116.4M | $88.2M | +32% |
The entire +32% growth came from ex-US launches; US revenue has plateaued. The US captured ~1,200 of >3,000 DEB patients at launch; the flat US line says the company is now near its addressable US ceiling on the original label and is leaning on (a) the Sept-2025 label expansion (birth-onward + caregiver/self-administration) and (b) new geographies for growth. This is the bull/bear fault line: is the US plateau a temporary mix/timing artifact, or the franchise hitting its US asymptote?
Full-year scale: FY2025 net product revenue $389.1M (+33.9% vs $290.5M FY2024; FY2023 $50.7M partial-year). Gross margin 94% FY2025 / 95% Q1-2026.
Customer concentration (a Lens-13 input surfaced here): Customer A = 62% of net AR (Mar-31-2026), Customer B = 13% — i.e. ~75% of receivables sit with two specialty-pharmacy customers. AR of $127.0M against quarterly revenue of $116.4M ⇒ DSO ≈ 98 days. High and worth watching.
The latest quarter is a clean beat with expanding margins:
Full-year FY2025, in $000s:
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Product revenue, net | 389,130 | 290,515 | 50,699 |
| Cost of goods sold | 23,049 | 20,061 | 3,094 |
| Research & development | 58,045 | 53,580 | 46,433 |
| SG&A | 146,741 | 113,626 | 98,289 |
| Litigation settlement | — | 37,500 | 12,500 |
| Income (loss) from operations | 161,295 | 65,748 | (109,617) |
| Interest & other income, net | 28,176 | 29,608 | 22,514 |
| Gain on PRV sale | — | — | 100,000 |
| Income before tax | 189,471 | 95,356 | 12,897 |
| Income tax benefit (expense) | 15,360 | (6,197) | (1,965) |
| Net income | 204,831 | 89,159 | 10,932 |
| Diluted EPS | $6.84 | $3.00 | $0.39 |
Read-throughs / flags: (1) FY2025 is the first year of clean, structural operating profitability — $161.3M operating income (41% op margin) with no one-time crutch, vs FY2024 (dragged by a $37.5M PeriphaGen settlement) and FY2023 (operating loss of −$109.6M masked by a $100M priority-review-voucher sale). (2) FY2025 net income is flattered by a one-time +$15.4M deferred-tax valuation-allowance release — normalize tax to ~13–15% and "clean" FY2025 EPS is closer to ~$5.7–6.0. (3) Operating cash flow +$200.9M FY2025 (net income $204.8M + $54.5M SBC, less $36.4M working-capital build and $22.8M deferred-tax change); capex only $12.0M ⇒ FCF ≈ $188.9M. (4) SBC $54.5M = ~14% of revenue — a material non-GAAP flatter; watch it (Lens 10). (5) Retained earnings turned positive (+$24.2M at year-end) — the company has crossed into cumulative profitability.
Minor filing oddity: the FY2024 cash-flow narrative reads "net cash used by operating activities … $123.4M" while the arithmetic ($89.2M NI + $48.7M non-cash add-backs) implies cash provided of ~$123M. Reads as a stale-template wording error in the 10-K, not a real FY2025 cash issue — FY2025 OCF is unambiguously +$200.9M.
No transcripts in the research layer (transcripts/ empty), so this is web/filing-inferred and labeled accordingly. The consistent management narrative across FY2025 → Q1-2026:
Peer set = profitable/scaling commercial rare-disease & cell/gene-therapy names. Multiples are `` with date or n/a.
| Company | Ticker | Mkt cap (USD) | EV/Sales | P/E (TTM) | P/S | Note |
|---|---|---|---|---|---|---|
| Krystal Biotech | KRYS | ~$10.3B @ $348 (2026-06-18) | ~24x FY25 / ~20x NTM run-rate | ~38–51x (see note) | ~23x | Profitable, net cash ~$1.0B, +32% growth |
| Vericel | VCEL | ~$1.9B (2026-06-14) | n/a | ~92x | ~5.8x | Closest profitable "repeat cell-therapy specialty" peer |
| Insmed | INSM | ~$30B+ (2026) | n/a | neg (unprofitable) | ~24x | Hyper-growth (BRINSUPRI), not yet profitable |
| Ultragenyx | RARE | ~$2.5B (2026-05) | n/a | neg (EPS −$6.11) | ~3.8x | Rare-disease, unprofitable |
| Argenx | ARGX | ~$55.7B (2026) | n/a | n/a | ~13.4x (2025 sales) | Scaled, profitable; growth +90% |
KRYS P/E ambiguity: TTM GAAP EPS $6.84 ÷ $348 = ~51x; the lower ~38x trailing / ~33x forward figures from stockanalysis reflect a lower price snapshot and/or NTM EPS. Either way KRYS trades rich on earnings but is one of the only profitable names in the comp set — the EV/Sales of ~20–24x prices it like a high-growth pre-profit biotech despite already being profitable, i.e. the market is paying for the pipeline option + ex-US ramp, not just the DEB annuity. PEG ~0.60 says the multiple is not crazy if the ~20%/yr growth holds.
52-week range $128 → $357; ~2.7x off the low, +139% 1-yr total shareholder return. The pattern of what actually moves the stock:
| Asset | Indication | Modality | Stage | Next catalyst |
|---|---|---|---|---|
| VYJUVEK | DEB | topical HSV-1 / COL7A1 | Commercial (US/EU/JP/UK) | Italy launch H2-2026; further EU pricing; UK NICE/reimbursement (NICE decision ~Jul-2026 ) |
| Inhaled KB707 | 2L NSCLC | inhaled IL-2/IL-12 immunotherapy | Ph1/2 (KYANITE-1) → Phase 3 path agreed; RMAT | Interim combo-w/chemo data + registrational plan 2026; ORR 36% monotherapy in heavily-pretreated NSCLC |
| KB803 | Ocular complications of DEB | eye-drop B-VEC | Ph3 registrational (IOLITE) | Enrollment complete H1-2026; top-line 2026 |
| KB801 | Neurotrophic keratitis | eye-drop NGF | Registrational (EMERALD-1); platform-tech designation | Top-line 2026 (~60 pts) |
| KB407 | Cystic fibrosis | inhaled CFTR | Ph1 (CORAL-1) → CORAL-3 | Registrational CORAL-3 start H1-2026 |
| KB408 | AATD lung disease | inhaled SERPINA1 | Ph1 (SERPENTINE-1) | Repeat-dose interim 2026 |
| KB111 | Hailey-Hailey disease | topical ATP2C1 | IND cleared (Oct-2025) | Registrational study start H2-2026 |
| KB304 / KB301 | Aesthetics (décolleté/wrinkles) | intradermal COL3A1/ELN — Jeune Aesthetics | Ph1 positive (PEARL-2/-1) | KB304 Phase 2 start 2027 |
| Intratumoral KB707 | Solid tumors/melanoma | injected IL-2/IL-12 | Ph1/2 (OPAL-1) — enrollment paused (deprioritized) | follow-up only |
Sources:; trial status.
Founder-led, and the founders have done this before — well.
Acting as a forensic equity analyst. The accounting is clean and conservative for a company this profitable, but there are three real items:
Regulatory findings (required sub-section):
Built bottom-up from the Q1-2026 run-rate ($116.4M rev, 46% op margin, 95% GM) and the launch cadence. Fiscal year = calendar year. Every input labeled; outputs ``.
Revenue drivers: US flat-to-+low-single-digit (label expansion vs near-saturation); Europe ramping (Germany live, France via early-access, Italy H2-2026, UK reimbursement pending); Japan ramping; distributor markets additive. Net tax normalizes to ~14–15% (no repeat of the FY25 allowance release).
| Scenario | FY2026E rev | FY2027E rev | FY2028E rev | FY2026E dil. EPS | FY2028E dil. EPS |
|---|---|---|---|---|---|
| Bull | ~$540M | ~$680M | ~$820M | ~$8.6 | ~$13 |
| Base | ~$510M | ~$610M | ~$710M | ~$7.8 | ~$10.5 |
| Bear | ~$470M | ~$500M | ~$520M | ~$6.6 | ~$7.0 |
Pipeline rNPV / catalyst-runway note (overlay): with ~$1.0B net cash, +$189M FCF, and GAAP profitability, runway is a non-issue — Krystal reaches every near-term value-inflection catalyst (KB803, KB801, KB407, KB707) self-funded. The optionality is therefore free-carried by the DEB cash machine. The highest-value un-priced shot is inhaled KB707 in 2L NSCLC — 36% monotherapy ORR in heavily-pretreated patients + FDA-blessed single-Phase-3 path + RMAT. A meaningful NSCLC win is a multi-billion-dollar TAM that dwarfs DEB; a fail costs little because it's not in the base. I do not put a point rNPV on KB707 — peak-sales × PoS × discount would be a fabricated multiple here; flag it as the asymmetric option, not a modeled line.
(Per --watchlist rules, no forecast.ts create was run — logging the Brier forecast is reserved for a committed base case in a /thesis pass. Candidate forecast to log there: "KRYS FY2026 diluted EPS ≥ $7.50", p≈0.55, resolves 2027-02-28.)
Bull case. A rare thing in biotech: a profitable, self-funded, founder-run gene-therapy platform with a four-market orphan monopoly (VYJUVEK), 95% gross margins, ~$1B net cash, +$189M FCF, and a deep multi-asset registrational pipeline that's free-carried by the cash machine. The platform (re-dosable HSV-1, FDA platform-tech designation) is a repeatable engine — DEB was the proof, and 2026 brings four registrational shots on goal (KB803, KB801, KB407, KB707) plus optional aesthetics (a consumer-pay, non-orphan TAM via Jeune). The founders did a $2.6B exit before and own ~5%+. If even one pipeline asset lands — especially inhaled KB707 in NSCLC (a TAM orders of magnitude larger than DEB) — the current ~$10B cap looks early. Contrarian read: the market is treating KRYS as a one-drug orphan story when it is actually a profitable platform with a portfolio of cheap call options the P&L pays for.
Bear case. Three things could permanently impair or de-rate it: (1) the US plateau is structural, not timing — US revenue is already flat YoY with the franchise near its addressable ceiling; ex-US ramp is finite and pricing-negotiation-gated (Germany H2-2026, France 2027), so total VYJUVEK revenue could asymptote near ~$500–600M while SG&A keeps climbing. (2) The pipeline is a basket of un-de-risked binaries — none is approved; KB707/NSCLC is a Phase-1/2 signal in 11 evaluable patients, ophthalmology and CF readouts are 2026 coin-flips; a clustered set of misses in 2026 would strip the "platform" premium and leave a ~$500M-revenue orphan drug trading at >15x sales. (3) Concentration + the DOJ tail — 75% of receivables in two customers, plus an open DOJ inquiry into the sponsored genetic-testing program (anti-kickback/false-claims-adjacent) that is, by the company's own words, not loss-estimable. Pre-mortem (18 months out, thesis broke): US DEB revenue declined, two pipeline readouts (KB801/KB803) disappointed or were equivocal, EU pricing came in lower than hoped, the DOJ matter produced a settlement/headline — and a stock priced at ~50x earnings / ~23x sales for platform hopes re-rated to a ~20x-earnings single-product orphan, i.e. a 40–55% drawdown with no permanent business impairment but a brutal multiple reset. Are multiples too high? Yes on earnings (~50x TTM GAAP) — justified only if the pipeline converts.
Dismantling the bull case. The whole long thesis is "platform, not product" — short it by attacking exactly that. Revenue is 100% one drug, and that drug's home market is already shrinking (US −0.8% YoY) — every dollar of growth is a new-launch sugar-high (Germany/Japan) that annualizes away, and the remaining EU launches are gated by pricing authorities who hold the leverage (negotiations dragging into 2027). The moat is narrower than bulls claim: Abeona's ZEVASKYN is now FDA-approved and commercially launched for RDEB — a genuine competitor for the most severe patients, and a reminder that DEB is no longer an uncontested monopoly. The pipeline "platform" is unproven in the only way that counts — zero second approvals — and the flagship KB707/NSCLC efficacy rests on an 11-evaluable-patient cohort whose ORR moved around (27% → 36% on re-cut); single-arm, heavily-pretreated, no controlled survival data — exactly the profile that disappoints in Phase 3. Capital-allocation skeletons: a $75M trade-secret settlement (PeriphaGen) over the platform's foundational IP, an open DOJ subpoena into how they find/test patients (the engine of the US launch), and a derivative suit over director pay — a governance cluster around a husband-wife control bloc. Assumptions that must hold for ~$348: ≥20% revenue CAGR for 3+ years and at least one major pipeline win and no adverse DOJ outcome and EU pricing at orphan-premium levels. If growth disappoints 20–30% (revenue plateaus ~$500M, EPS stalls ~$7), a ~50x P/E compresses to ~20–25x ⇒ $170–220 fair value, i.e. 35–50% downside. Single scenario that permanently impairs: the DOJ inquiry concludes the sponsored-testing/patient-identification program violated anti-kickback/false-claims law → a settlement + a forced change to the very patient-finding machine that drove the US launch → both a cash penalty and a structural hit to demand generation. Plausibility: low-to-moderate, but it's the real tail and it is not in any bull model.
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to.
A one-asset, binary bet on a genuinely best-in-class disease-modifying Dravet drug whose pivotal read-out (mid-2027) lands inside a fully-funded runway — own it for the read-out, but size it like the 50/50 single-trial event it is.